Medical and health industry weekly (October 21-25)

Content joint release: CCID consultant, Sina pharmaceutical Data source: brain of CCID medical and health industry This week, two policies and regulations were issued, among which the notice on printing and distributing technical specifications and grouping schemes of DRG paid countries was the key policy of this week, which was officially released by the State Health Insurance Bureau on October 23 Table 1 list of policies and regulations issued from October 21 to October 25 On October 23, the National Medical Security Bureau issued the notice on printing and distributing the technical specifications and grouping scheme of DRG paid national pilot (hereinafter referred to as the notice) At the same time, the national medical security DRG grouping and payment technical specifications (hereinafter referred to as the technical specifications) and the national medical security DRG (chs-drg) grouping scheme (hereinafter referred to as the grouping scheme) were officially released The technical specifications and group plan are authoritative and professional documents formulated under the unified guidance of the state, forming the basic compliance of the national health insurance DRG (chs-drg) The release of the two documents aims to create a pilot "one chess", precise "localization", specific payment in line with the actual situation of each place, making chs-drg become the "common language" in the field of national health insurance In May this year, the National Health Insurance Bureau released the list of 30 pilot cities for DRG payment In this notice, all pilot cities are required to follow the basic principles, scope of application, definition of terms, data requirements, data quality control, standardized uplink specifications, grouping strategies and principles, weight and rate determination and other requirements of DRG grouping as determined in the technical specifications; requirements Strictly implement the grouping scheme, formulate the local sub DRG grouping according to the unified grouping operation guide and the actual situation of each region; emphasize the use of five information business codes of medical insurance disease diagnosis and operation, medical service project, medicine, medical consumables and medical insurance settlement list in the pilot cities according to the requirements; require the establishment of the local DRG payment pilot work talent team In the pilot work of DRG payment, the National Medical Security Bureau has taken another key step A total of 133 drug registration applications (excluding reexamination) were accepted this week By drug category, the number of chemical drug registration applications was the largest, accounting for 111 cases, accounting for 83%; the number of biological products and traditional Chinese medicine registration applications accounted for 12% and 5%, respectively According to the classification of registration application types, 82 cases are supplementary applications, accounting for 62%; the acceptance of generic drugs accounts for 17%; the acceptance of new drugs accounts for 12%; and the acceptance of imported drugs accounts for 9% Figure 1 drug categories accepted for registration and declaration in China this week Figure 2 types of drug registration and declaration accepted nationwide this week This week, the company with the largest number of applications for registration of drugs was Beijing feisenyuskabi Pharmaceutical Co., Ltd., with 20 cases accepted, followed by anstelai Pharmaceutical (China) Co., Ltd., with 8 cases accepted Figure 3 the number of drug registrations declared by enterprises in China this week top 10 In terms of consistency evaluation, there are 20 application numbers in total this week, mainly involving 18 drug categories such as terlipressin for injection, mifepristone tablet, docetaxel injection, Cefalexin tablet, chlorphenamine maleate tablet, calcium acetate tablet, etc., among which the consistency evaluation of Cefalexin tablet of Shandong Xinhua Pharmaceutical Co., Ltd and doxofylline injection of Shanxi Guorun Pharmaceutical Co., Ltd Application number reached 2 Table 2 list of conformity assessment application No from October 21 to October 25 This week, 7 applications for conformity assessment have been approved and are in the stage of certificate preparation Among them, Cefalexin tablets of Shandong Xinhua Pharmaceutical Co., Ltd have two acceptance numbers Table 3 review status of consistency evaluation from October 21 to October 25 In terms of the mainland investment and financing market, there were 5 investment and financing events in the field of medicine and health this week, of which 2 events disclosed a total amount of 110 million yuan The investment targets are Weimai medical, pharmaceutical convenience, donofi, Yiming cell and Santan medical, mainly involving medical services, pharmaceutical retail, biological drugs and medical devices In terms of the disclosed amount, the highest amount of financing is dennofi, reaching 100 million yuan Table 4 mainland investment and financing events from October 21 to October 25 On October 21, Hefei dengtefei Medical Equipment Co., Ltd (hereinafter referred to as "dengtefei") officially announced that it has obtained an angel round financing of 100 million yuan The investor is a consortium composed of the chairmen of several listed enterprises Most of the investors master the core technology in the field of optoelectronic identification in China, and the products are widely used in large enterprises in aerospace, military, automobile, petrochemical and other fields The shareholders have strong strength, and they are optimistic about the future of dennofi Founded in May 2019, dengtefei mainly focuses on the oral medical market Its commercial core is the oral imaging equipment and supporting software system platform At present, dengtefei has more than 60% of the company's core R & D members, most of whom graduated from famous domestic universities such as China University of science and technology, northwest Polytechnic University and Hegong University, with master's degree and doctor's degree accounting for more than 80% Based on the strong R & D strength, the research and development team of dengtefei has completed the dental CBCT, Cr, surgical microscope and other projects within half a year, and has launched more projects including intraoral scanner, cutting machine, 3D printing, periodontal fiber endoscope and so on The equipment developed by detefei has industry-leading technology and functions, which will provide accurate diagnosis basis for dental medical institutions and fully release the potential of domestic equipment to replace imported equipment, which will become a high-quality data entry This round of financing funds are mainly used in the field of digital imaging equipment for in-depth layout The products will cover the digital planting, digital correction, root canal diagnosis and treatment, restoration, periodontal fine diagnosis and treatment and other general dentistry At the same time, dengtefei plans to build 50 provincial supplies distribution centers, a large-scale comprehensive denture design and processing center and a large-scale oral equipment Industrial Park in China In terms of overseas investment and financing market, there have been three major investment and financing events in the field of medical health this week, with a total financing amount of about 1 billion yuan The investment targets are lygenesis, arcutis biotherapeutics and Verseau therapeutics, mainly involving the field of biotechnology Among them, Verseau therapeutics, with a US $50 million financing, will be used to support the clinical application of macrophage almost regulator, which is a new type of tumor immunotherapy pioneered in the world Table 5 overseas investment and financing events from October 21 to October 25